Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis

Table 1 Visceral leishmaniasis-HIV co-infection and treatment success

	Studies	HIV- (Sample/ Total)	HIV+ (Sample/ Total)	OR (95% CI)	P-value	I ²
EOT
Overall treatment success	6 studies [21, 22, 25, 28,29,30]	784/819	345/485	7.53 (4.93–11.50)	0.482	0.00%
SSG treatment success	3 studies [18, 28, 29]	392/411	93/119	6.09 (2.84–13.04)	0.272	23.09
6MFU
Overall treatment success	4 studies [21, 28,29,30]	346/374	77/161	11.33 (6.78–18.91)	0.609	0.00%
SSG treatment success	2 studies [28, 29]	211/224	35/58	11.66 (4.13–31.53)	0.206	37.36

Note: OR odds ratio, CI confidence interval, EOT End of treatment, 6MFU 6 months follow-up

ISSN: 2049-9957